Assessing nitric oxide components in asthma and COPD patients
The Clinical Value of the Nitric Oxide System Components in Asthma and Chronic Obstructive Pulmonary Disease
This study is trying to see if measuring certain nitric oxide levels in people with asthma and COPD can help us understand their condition better and find new ways to prevent flare-ups.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 240 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Ryazan State Medical University Academic / other |
| Locations | 1 site (Ryazan', Ryazanskaya Obl.) |
| Trial ID | NCT04456491 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the levels of nitric oxide metabolites, L-arginine, arginase-1, and asymmetric dimethylarginine in patients diagnosed with bronchial asthma and chronic obstructive pulmonary disease (COPD). By observing these biomarkers, the research seeks to enhance the understanding of disease prognosis and potentially identify new methods for predicting and preventing exacerbations. The study focuses on the role of nitric oxide in respiratory diseases, which are characterized by persistent inflammation and systemic dysfunction. The findings could contribute to personalized medicine approaches in managing these conditions.
Who should consider this trial
Good fit: Ideal candidates include men and women aged 18 to 70 with a diagnosis of asthma or COPD according to current guidelines.
Not a fit: Patients with severe cardiovascular issues, liver dysfunction, or significant renal impairment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved methods for predicting and managing asthma and COPD exacerbations.
How similar studies have performed: While the approach of using nitric oxide metabolites as biomarkers is established, the specific application in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * men and women aged between 18 and 70 years * a diagnosis of asthma or chronic obstructive pulmonary disease according to actual GINA and GOLD guidelines Exclusion Criteria: * decompensated pathology of the cardiovascular system; * history of liver dysfunction accompanied by an increase in ALT, AST or total bilirubin more than 3 times higher than the upper limit of normal; * history of severe renal impairment, accompanied by a decrease in glomerular filtration rate below 60 ml/min (according to CKD-EPI); * abuse on psychoactive substances and / or alcohol.
Where this trial is running
Ryazan', Ryazanskaya Obl.
- Department of Therapy — Ryazan', Ryazanskaya Obl., Russian Federation (Recruiting)
Study contacts
- Principal investigator: Anton Shakhanov, MD, Cand.Sci. (Med.) — Ryazan State Medical University
- Study coordinator: Anton Shakhanov, MD, Cand.Sci. (Med.)
- Email: shakhanovav@gmail.com
- Phone: +7 910 635-95-75
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.